Genethon relaunches itself as a force for translational medicine.
Archive for the ‘Gene therapy’ category
French institute prepares for gene-therapy push
January 25th, 2012Penn researchers report gain in using gene therapy to battle blindness
January 25th, 2012Four years ago, teams of researchers at the University of Pennsylvania and elsewhere made headlines by restoring some sight to blind people, though it was a form of blindness few had heard of.
Go here to see the original:
Penn researchers report gain in using gene therapy to battle blindness
UK sets sights on gene therapy in eggs
January 25th, 2012Public consultation and safety assessment would pave the way for embryo manipulation to treat genetic diseases.
See the article here:
UK sets sights on gene therapy in eggs
Gene therapy is a 'disruptive science' ready for commercial development
January 25th, 2012The time for commercial development of gene therapy has come. Patients with diseases treatable and curable with gene therapy deserve access to the technology, which has demonstrated both its effectiveness and feasibility, says James Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy in a provocative commentary and accompanying videocast
See the article here:
Gene therapy is a 'disruptive science' ready for commercial development
Gene therapy research cures retinitis pigmentosa in dogs
January 24th, 2012Members of a University of Pennsylvania research team have shown that they can prevent, or even reverse, a blinding retinal disease, X-linked Retinitis Pigmentosa, or XLRP, in dogs.
Go here to read the rest:
Gene therapy research cures retinitis pigmentosa in dogs
Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
January 24th, 2012( University of Pennsylvania ) Members of a University of Pennsylvania research team have shown that they can prevent, or even reverse, a blinding retinal disease, X-linked Retinitis Pigmentosa, or XLRP, in dogs.The disease in humans and dogs is caused by defects in the RPGR gene and results in early, severe and progressive vision loss. It is one of the most common inherited forms of retinal …
Go here to see the original:
Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
Gene therapy cures retinitis pigmentosa in dogs
January 24th, 2012Scientists have shown that they can prevent, or even reverse, a blinding retinal disease, X-linked Retinitis Pigmentosa, or XLRP, in dogs. The disease in humans and dogs is caused by defects in the RPGR gene and results in early, severe and progressive vision loss.
Originally posted here:
Gene therapy cures retinitis pigmentosa in dogs
Gene therapy that could correct common form of blindness developed
January 24th, 2012Washington, Jan 24 (ANI): Researchers have developed a new gene therapy method that has the potential to treat a common form of blindness, which strikes both youngsters and adults.
Read more here:
Gene therapy that could correct common form of blindness developed
New gene therapy shows promise against X-linked retinitis pigmentosa
January 24th, 2012A new gene therapy [1] method developed by University of Florida researchers has the potential to treat a common form of blindness that strikes both youngsters and adults. The technique works by replacing a malfunctioning gene [2] in the eye with a normal working copy that supplies a protein necessary for light-sensitive cells in the eye to function.
More:
New gene therapy shows promise against X-linked retinitis pigmentosa
Researchers develop gene therapy that could correct a common form of blindness
January 24th, 2012( University of Florida ) A new gene therapy has the potential to treat a common form of blindness that strikes both youngsters and adults. The technique works by replacing a malfunctioning gene in the eye with a normal working copy that supplies a protein necessary for light-sensitive cells in the eye to function. Several complex steps remain before the gene therapy technique can be used in …
See the article here:
Researchers develop gene therapy that could correct a common form of blindness
BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis
January 22nd, 2012Authors: H Teoh, A Quan, A K Creighton, K W Annie Bang, K K Singh, P C Shukla, N Gupta, Y Pan, F Lovren, H Leong-Poi, M Al-Omran
& S Verma (Source: Gene Therapy)Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs
January 22nd, 2012Authors: B L Ellis, M L Hirsch, S N Porter, R J Samulski
& M H Porteus (Source: Gene Therapy)Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
January 22nd, 2012The costimulatory effects of CD27 on T lymphocyte effector function and memory formation has been confined to evaluations in mouse models, in vitro human cell culture systems, and clinical observations. Here, we tested whether CD27 costimulation actively enhances human T-cell function, expansion, and survival in vitro and in vivo. Human T cells transduced to express an antigen-specific chimeric antigen receptor (CAR-T) containing an intracellular CD3 zeta (CD3) chain signaling module with the CD27 costimulatory motif in tandem exerted increased antigen-stimulated effector functions in vitro, including cytokine secretion and cytotoxicity, compared with CAR-T with CD3 alone. After antigen stimulation in vitro, CD27-bearing CAR-T cells also proliferated, up-regulated Bcl-XL protein expression…Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
Sendai virus vector?mediated brain?derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer’s disease
January 22nd, 2012AbstractGrowing evidence suggests that decreased brain?derived neurotrophic factor (BDNF) levels are associated with Alzheimer’s disease (AD) pathogenesis. Therefore, BDNF gene therapy is considered to be a promising therapeutic strategy for treating AD. Sendai virus (SeV) is a type I parainfluenza virus that does not interact with host chromosomes because of its strict cytoplasmic life cycle. Although SeV is nonpathogenic in primates, including humans, its infectivity for neurons is strong. Here we demonstrate that SeV vectors effectively infected neurons, even though they were injected into subcortical white matter. Moreover, SeV vectors significantly induced BDNF expression, ameliorating synaptic degeneration and memory deficits in a transgenic mouse model of AD (Tg2576). This is the …
MedWorm Sponsor Message: Find the best January Sales in the UK.
Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
How Has Stephen Hawking Lived to 70 with ALS?
January 22nd, 2012Stephen Hawking turns 70 on Sunday, beating the odds of a daunting diagnosis by nearly half a century. [More]
Source:Genes May Give Clues to Severe form of Lupus
January 22nd, 2012A DNA sequence known as an ‘accelerator’ might explain some aggressive cases, researchers say
Source: HealthDay
Related MedlinePlus Pages: Genes and Gene Therapy, Lupus (Source: MedlinePlus Health News)Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
Genes May Guide Intelligence Throughout Life
January 22nd, 2012Some people stay smart as they age in part because of genetic factors, study suggests
Source: HealthDay
Related MedlinePlus Page: Genes and Gene Therapy (Source: MedlinePlus Health News)Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
Study Maps Path from Smoking to Emphysema in Mice
January 22nd, 2012Immune response to smoke causes the disease, researchers say
Source: HealthDay
Related MedlinePlus Pages: Genes and Gene Therapy, Smoking (Source: MedlinePlus Health News)Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies
January 22nd, 2012Human Gene Therapy , Vol. 0, No. 0. (Source: Human Gene Therapy)Source:
http://www.medworm.com/rss/medicalfeeds/therapies/Gene-Therapy.xml
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research
